New intravenous combination antibiotic for intra-abdominal and urinary tract infection

Zerbaxa contains the cephalosporin ceftolozane and the beta-lactamase inhibitor tazobactam.

Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock
Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock

Further information
View Zerbaxa drug record 
Summary of Product Characteristics
Manufacturer: Merck Sharp & Dohme

The combination is administered by intravenous infusion and is indicated for the treatment of complicated intra-abdominal infection, complicated urinary tract infection and acute pyelonephritis. Susceptible organisms include Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae.

In a trial in patients with complicated intra-abdominal infection, clinical cure rates for the ceftolozane/tazobactam combination were 95.9% in patients younger than 65 years (n=293) and 87.8% in those 65 years or older (n=82).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases